Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
7.75
-0.25 (-3.13%)
At close: Oct 6, 2026, 4:00 PM EDT
7.75
0.00 (0.00%)
After-hours: Oct 6, 2026, 4:10 PM EDT
Verastem Revenue
Verastem had revenue of $40.08M in the quarter ending June 30, 2026, with 1,775.43% growth. This brings the company's revenue in the last twelve months to $87.53M, up 3,995.74% year-over-year. In the year 2025, Verastem had annual revenue of $30.91M with 209.14% growth.
Revenue (ttm)
$87.53M
Revenue Growth
+3,995.74%
P/S Ratio
8.26
Revenue / Employee
$858,098
Employees
102
Market Cap
701.87M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 30.91M | 20.91M | 209.14% |
| Dec 31, 2024 | 10.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
| Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
| Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
| Dec 31, 2019 | 17.46M | -9.26M | -34.67% |
| Dec 31, 2018 | 26.72M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| MiMedx Group | 355.17M |
| Wave Life Sciences | 65.37M |
| OmniAb | 38.46M |
| Shattuck Labs | 1.00M |
VSTM News
- 1 day ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 days ago - Verastem announces data from analysis of Phase 2 RAMP 201 trial - TheFly
- 4 days ago - Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026 - Business Wire
- 8 days ago - Verastem announces publication of RAMP 201 study in Gynecologic Oncology journal - TheFly
- 8 days ago - Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer - Business Wire
- 12 days ago - Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire
- 19 days ago - Verastem initiated with an Outperform at Wolfe Research - TheFly
- 22 days ago - Verastem Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts